Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP

• Published in: Journal of pathology and translational medicine Vol. 58; no. 4; pp. 147 - 164
• Main Authors: Kim, Miso, Shim, Hyo Sup, Kim, Sheehyun, Lee, In Hee, Kim, Jihun, Yoon, Shinkyo, Kim, Hyung-Don, Park, Inkeun, Jeong, Jae Ho, Yoo, Changhoon, Cheon, Jaekyung, Kim, In-Ho, Lee, Jieun, Hong, Sook Hee, Park, Sehhoon, Jung, Hyun Ae, Kim, Jin Won, Kim, Han Jo, Cha, Yongjun, Lim, Sun Min, Kim, Han Sang, Lee, Choong-Kun, Kim, Jee Hung, Chun, Sang Hoon, Yun, Jina, Park, So Yeon, Lee, Hye Seung, Cho, Yong Mee, Nam, Soo Jeong, Yoon, Sun Och, Lee, Ahwon, Jang, Kee-Taek, Yun, Hongseok, Lee, Sungyoung, Kim, Jee Hyun, Kim, Wan-Seop
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Society of Pathologists, Korean Society for Cytopathology 01.07.2024; The Korean Society of Pathologists and the Korean Society for Cytopathology; Korean Society of Pathologists & the Korean Society for Cytopathology; 대한병리학회
• Subjects: Biomarkers; Bone cancer; Clinical medicine; Clinical trials; Ewings sarcoma; FDA approval; Genes; Genetic testing; Kidney cancer; korea; Metastasis; Mutation; next-generation sequencing; Oncology; Patients; Precision medicine; Regulatory approval; Review; Rhabdomyosarcoma; solid cancer; Tumors; 병리학; Next-generation sequencing; Solid cancer; Precision medicine; Korea
• ISSN: 2383-7837; 2383-7845
• DOI: 10.4132/jptm.2023.11.01

In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.